Press coverage about BIO-TECHNE (NASDAQ:TECH) has been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BIO-TECHNE earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.7076191496175 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- 3 Reasons Momentum Stock Investors Will Love Bio-Techne (TECH) (zacks.com)
- Stem Cell Assay Market – Higher Growth Rate & Forecast 2017 – 2025 (openpr.com)
- Bio-Techne Expands RNAscope® ISH Automation – Facilitating Drug Discovery and Development (prnewswire.com)
- BidaskClub Upgrades BIO-TECHNE (TECH) to “Strong-Buy” (americanbankingnews.com)
- Bio-Techne introduces MimEX GI, an accessible 3-D cell culturing platform for the GI tract (pharmabiz.com)
BIO-TECHNE stock traded down $0.53 during mid-day trading on Thursday, hitting $147.92. 32,354 shares of the company were exchanged, compared to its average volume of 180,832. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.10 and a quick ratio of 2.49. BIO-TECHNE has a 12-month low of $98.22 and a 12-month high of $149.68. The stock has a market capitalization of $5,571.63, a price-to-earnings ratio of 40.85, a price-to-earnings-growth ratio of 2.85 and a beta of 0.75.
The company also recently announced a quarterly dividend, which was paid on Friday, March 2nd. Investors of record on Friday, February 16th were paid a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, February 15th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.87%. BIO-TECHNE’s payout ratio is 41.97%.
Several analysts recently issued reports on TECH shares. Zacks Investment Research upgraded shares of BIO-TECHNE from a “hold” rating to a “buy” rating and set a $158.00 price objective on the stock in a report on Saturday, January 20th. Leerink Swann reiterated a “buy” rating on shares of BIO-TECHNE in a research note on Tuesday, December 5th. Robert W. Baird reiterated a “buy” rating and set a $154.00 price target on shares of BIO-TECHNE in a research note on Thursday, January 18th. BidaskClub upgraded shares of BIO-TECHNE from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 16th. Finally, Deutsche Bank set a $163.00 price target on shares of BIO-TECHNE and gave the stock a “buy” rating in a research note on Thursday, March 1st. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $148.60.
In related news, Director Charles A. Dinarello sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $136.06, for a total transaction of $680,300.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.40% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “BIO-TECHNE (TECH) Earns Daily News Sentiment Score of 0.18” was first reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/2018/03/22/bio-techne-tech-given-media-impact-score-of-0-18/1927559.html.
BIO-TECHNE Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.